News 16.06.2021 Zurich-Schlieren, Switzerland, June 16, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ("ADSs") at a public offering price...
News 14.06.2021 Zurich-Schlieren, Switzerland, June 13, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that the first patient has been dosed in a new Phase 3 sub-study evaluating ensovibep, as part of the National Institutes of...
News 09.06.2021 Zurich-Schlieren, Switzerland, June 9, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial public offering in the United States of 3,000,000 American Depositary Shares ("ADSs") pursuant to a registration...
News 02.06.2021 Schlieren (Zurich), Switzerland, June 2, 2021 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today provided an update on its commercial activities, with sales of MagnetOs bone graft and progress in establishing distributor networks both exceeding management expectations. Direct sales of MagnetOs in the U.S. accelerated in...
News 27.05.2021 Zurich-Schlieren, Switzerland, May 27, 2021. Molecular Partners (SIX: MOLN) and Novartis announced today the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis will conduct the clinical trial program...